...
EDITMICRO

Editas Medicine, Inc.

HealthcareBiotechnology
$2.20
$0.00(+0.92%)
52W$0.91
$4.54
FinancialsValuationvs ALNY
Updated Feb 28, 12:00 AM
RSI61
RS Rating31/99
Beta2.10
Volatility98%
F-Score2/9
Mkt Cap$205M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Editas Medicine, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 31), showing significant lag compared to the market leaders. Earnings growth of 63% provides fundamental context to the price action. Investors should exercise caution due to high volatility (98% annualized), which requires wider risk management.

Relative Strength
31
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
2.10
vs S&P 500
HIGH BETA
52W Position
36%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$2.04
50 SMA > 100 SMA$2.50
100 SMA > 150 SMA$2.61
150 SMA > 200 SMA$2.52

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$1.89+16.25%ABOVE
50 SMA$2.04+7.59%ABOVE
100 SMA$2.50-11.85%BELOW
150 SMA$2.61-15.66%BELOW
200 SMA$2.52-12.68%BELOW

Price Performance

1D+0.9%
1W+16.4%
1M+6.8%
3M-8.7%
6M-17.0%
YTD+7.3%
1Y+14.6%
3Y-37.6%
52-Week Trading Range36% from low
$2.20
52W Low$0.91
52W High$4.54

Technical Indicators

RSI (14)BULLISH
61.2
305070
VCP ScoreCOOL
3/10
Base depth: 47.3%

Risk Profile

Beta
2.10
52W Vol
98%
ATR
$0.14
Max DD (1Y)
-60%

Volume Analysis

Today
2
50D Avg
1.48M
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24-139%
$-0.55
Q1'25-21%
$-0.92
Q2'25+23%
$-0.63
Q3'25+63%
$-0.28
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+9.50%
3 Years:+8.15%
TTM:-24.90%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+7.03%

Stock Price CAGR

10 Years:-22.72%
5 Years:-45.77%
3 Years:-37.57%
1 Year:+14.58%

Return on Equity

10Y Avg:-90.7%
5Y Avg:-53.1%
3Y Avg:-63.2%
Last Year:-1485.4%

Key Metrics

Market Cap$205M
Gross Margin1.0%
Net Margin-7.3%
Piotroski F-Score2/9

More EDIT Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

EDIT vs ALNYALNYIONSARWRCRSP

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 31 meansEDIT outperformed 31% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 2.10 means 110% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is EDIT in an uptrend right now?

EDIT has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is EDIT overbought or oversold?

EDIT's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.

Is EDIT outperforming the market?

EDIT has a Relative Strength (RS) Rating of 31 out of 99. EDIT is currently lagging the broader market.

Where is EDIT in its 52-week range?

EDIT is trading at $2.20, which is 48% of its 52-week high ($4.54) and 36% above its 52-week low ($0.91).

How volatile is EDIT?

EDIT has a Beta of 2.10 and 52-week volatility of 98%. It's more volatile than the S&P 500 - expect bigger swings.